Mode
Text Size
Log in / Sign up
N/A Completed N=120 Prevention

Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting

Carotid Artery Diseases · Stroke
Source: ClinicalTrials.gov NCT01783639 ↗
Enrolled (actual)
120
Serious AEs
15.0%
Results posted
Jul 2015
Primary outcomePrimary: The Rate of Peri-procedural (Within 30 Days of Procedure) Death, Stroke, and Myocardial Infarction. — 4 participants

Summary

The purpose of this study is to compare the safety and performance of WIRION™ EPD in patients undergoing carotid artery stenting to a performance goal based on an analysis of the results of previous US IDE carotid stenting with embolic protection studies

Outcome Measures

OutcomeResultp-value
PRIMARY
The Rate of Peri-procedural (Within 30 Days of Procedure) Death, Stroke, and Myocardial Infarction.
4 —
SECONDARY
The Rate of Device Success
— —
SECONDARY
The Rate of Clinical Success
— —
SECONDARY
The Rate of Access Site Complications
— —
SECONDARY
Neurological Events Occurring Within 30 Days Post Procedure,Including Strokes and Transient Ischemic Attacks
— —
SECONDARY
Angiographic Success
— —
SECONDARY
Procedural Success
— —

Eligibility Criteria

Inclusion Criteria

  • 18 years of age
  • Anticipated patient life expectancy of at least 1 year
  • Patient or authorized representative, signed a written Informed Consent form
  • Patient is willing to comply with the protocol requirements
  • Candidate for catheter-based therapy of a single stenosis located in the internal carotid artery (ICA) or the carotid bifurcation, suitable for treatment with a single FDA-approved stent with a carotid use indication
  • Reference vessel diameter for intended filter location between 3.5mm and 6.0mm
  • An adequate "landing zone" of at least 30mm
  • Patients with severe symptomatic or asymptomatic carotid artery stenosis, to be ≥ 50% for symptomatic patients OR ≥ 80% for asymptomatic patients
  • At least one high surgical risk criteria, either anatomical or co-morbid risk factors, as listed below:

Category I - Anatomical high risk factors

  • Recurrent stenosis after endarterectomy
  • Previous radical neck surgery or radiation therapy to the neck
  • High cervical ICA lesions or CCA lesions at or above C2 or below the clavicle
  • Spinal immobility of the neck
  • Tracheostomy or tracheal stoma
  • Any laryngeal nerve palsy and bilateral carotid artery stenosis

Category II - Co-morbid risk factors

  • Contralateral carotid occlusion
  • Unstable angina (Canadian Cardiovascular Society class III/IV)
  • Congestive Heart Failure (New York Heart Association functional class III/IV) and/or known severe left ventricular dysfunction LVEF 72 hr and <4 weeks)
  • Severe pulmonary disease with FEV1 of <30%
  • CAD in ≥2 unrevascularized vessels with stenosis ≥70%
  • Age ≥75 years
  • Uncontrolled diabetes - Female patient with no child bearing potential or has negative pregnancy test within the previous 7 days and agrees to remain on birth control throughout the study

Exclusion Criteria

  • Total occlusion or near-occlusion of the target vessel
  • Severe lesion calcification
  • Presence of an alternate source of emboli
  • Presence of a filling defect, or angiographically visible thrombus, at target site
  • A greater than 50% CCA lesion proximal to the target or a distal (intracranial) lesion more severe than the target lesion
  • Evolving, acute or recent stroke within the last 30 days
  • Major stroke with a residual neurological deficit that would confound neurologic assessment
  • Vertebrobasilar insufficiency symptoms only
  • Major operation 30 days before or after the index procedure
  • Ipsilateral intracranial stenosis that requires treatment
  • Any pre-existing stent in ipsilateral carotid artery, or placement of a stent in contralateral carotid within 30 days of the index procedure
  • History of intracranial hemorrhage within 12 months
  • Any condition that precludes proper angiographic assessment or prevents femoral arterial access
  • Uncontrolled hypertension
  • Contraindication to heparin and bivalirudin, aspirin, thienopyridines
  • Known sensitivity to radiographic contrast media which cannot be controlled with pre-medication
  • History or current indication of bleeding diathesis or coagulopathy
  • Chronic renal insufficiency
  • Carotid artery dissection or aortic arch anatomical anomalies
  • Dementia or a neurological illness
  • Patient is enrolled in another drug or device study protocol that has not reached its primary endpoint
  • Severe pulmonary hypertension
  • Intra-cranial pathology (e.g., tumor, AVM. aneurysm, etc) that would make study participation inappropriate or confound neurologic assessment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01783639). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search